在一个随机控制的第二阶段试验中,米里基祖马布对克罗恩病的组织学解决的作用
Fernando Magro1, Marijana Protic2, Gert De Hertogh3
1Department of Biomedicine, Faculty of Medicine of the University of Porto, Porto, Portugal.
概括
米里基祖马布治疗改善了克罗恩病的组织学愈合,显示出显著的反应和缓解率. 早期的组合组织学和内镜改善预测了长期内镜缓解.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药物开发 药物开发
背景情况:
- 粘膜愈合的组织学评估是克罗恩病管理的关键目标.
- 评估组织学结果有助于了解药物的疗效,并预测长期疾病的进展.
研究的目的:
- 为了评估mirikizumab在克罗恩病中的组织学疗效.
- 评估组织学反应与内镜/1年结局之间的关联.
主要方法:
- 170名参与者的活检样本在基线,第12周和第52周被分析.
- 组织学反应和缓解标准是根据中性粒细胞存在和活性得分来定义的.
- 评估了组织学和内镜终点之间的一致性,以及与1年结果的关联.
主要成果:
- 与安慰剂相比,Mirikizumab在第12周显著增加了组织学反应 (66%vs27%) 和缓解 (26%vs6%).
- 组织学反应和缓解率在1年后持续.
- 12周早期的结合组织学-内镜反应预测了1年内镜缓解 (45%对4%).
结论:
- 在克罗恩氏病的52周内,米里基祖马布有效诱导和维持组织学反应和缓解.
- 实现早期的结合组织学和内镜反应与有利的长期内镜结果有关.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
146
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
146
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Inflammatory Bowel Disease II: Crohn's Disease
256
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
256
Inflammatory Bowel Disease IV: Pharmacological Management
132
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
132
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
337
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
337


